First Tracks Biotherapeutics (TRAX)

The company’s lead clinical asset is rosnilimab, a selective pathogenic T cell depleter. Rosnilimab has been studied in a Phase 2b trial for moderate-to-severe rheumatoid arthritis, a large autoimmune market where many patients still do not achieve adequate disease control despite established biologic and targeted therapies. By aiming to deplete pathogenic T cells rather than broadly suppressing the immune system, the program seeks to address a central driver of autoimmune inflammation.

First Tracks is also advancing ANB033, a CD122 antagonist being evaluated in early clinical development for celiac disease and eosinophilic esophagitis. These are immune-related gastrointestinal disorders with significant unmet need, particularly where long-term disease control remains difficult. A further pipeline candidate, ANB101, is a BDCA2 modulator in Phase 1a testing, adding another mechanism to the company’s immunology-focused portfolio.

The business operates as a research and development organization rather than a diversified commercial pharmaceutical company. Its strategy is to build value by progressing differentiated immune-modulating candidates through clinical studies and, if successful, toward later-stage development and potential approval.